Randomized comparative efficacy and safety study of intermittent simvastatin versus fenofibrate in hemodialysis
Abstract
Aim: Compare the safety and efficacy of intermittent fenofibrate versus simvastatin in chronic hemodialysis patients. Patients & methods: Sixty patients received either fenofibrate 100 mg or simvastatin 20 mg after their dialysis session (parallel study). The safety and efficacy of drugs on lipid profile, oxidized low-density lipoprotein (Ox-LDL), glutathione peroxidase and C-reactive protein were compared before and after 16-week treatment. Results: After treatment, significant increase in glutathione peroxidase, significant decrease in total cholesterol, triglycerides, low density lipoprotein (LDL) and ox-LDL (p < 0.05) and no significant changes in C-reactive protein (p > 0.05) were observed in both groups. Both drugs were well tolerated with no serious side effects reported by the patients. Conclusion: Both drugs have comparable efficacy and safety when used as intermittent low dose regimen in hemodialysis. Larger studies with longer follow-up periods are needed to confirm our new findings.
Formats available
You can view the full content in the following formats:
References
Papers of special note have been highlighted as: •• of considerable interest
1.
Saran R, Li Y, Robinson B et al. US Renal Data System 2015 annual data report: epidemiology of kidney disease in the United States. Am. J. Kidney Dis. 67(3 Suppl. 1), S219–S226 (2016).
2.
Prichard SS. Impact of dyslipidemia in end-stage renal disease. J. Am. Soc. Nephrol. 14(9 Suppl. 4), S315–S320 (2003).
3.
Levey AS, Beto JA, Coronado BE et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on cardiovascular disease. Am. J. Kidney Dis. 32(5), 853–906 (1998).
4.
Sarnak MJ, Levey AS, Schoolwerth AC et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Hypertension 42(5), 1050–1065 (2003).
5.
Modaresi A, Nafar M, Sahraei Z. Oxidative stress in chronic kidney disease. Iran J. Kidney Dis. 9(3), 165–179 (2015).
6.
Moutzouri E, Kei A, Elisaf MS, Milionis HJ. Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid. Vasc. Health Risk Manag. 6, 525–539 (2010).
7.
Shurraw S, Tonelli M. Statins for treatment of dyslipidemia in chronic kidney disease. Perit. Dial. Int. 26(5), 523–539 (2006).
8.
Kirmizis D, Papagianni A, Dogrammatzi F et al. Effects of simvastatin on markers of inflammation, oxidative stress and endothelial cell apoptosis in patients on chronic hemodialysis. J. Atheroscler. Thromb. 17(12), 1256–1265 (2010).
9.
Nishikawa O, Mune M, Miyano M et al. Effect of simvastatin on the lipid profile of hemodialysis patients. Kidney Int. Suppl. 71, S219–S221 (1999).
10.
Shahbazian H, Atrian A, Yazdanpanah L, Lashkarara GR, Zafar Mohtashami A. Anti-inflammatory effect of simvastatin in hemodialysis patients. Jundishapur. J. Nat. Pharm. Prod. 10(1), e17962 (2015).
11.
Taccone-Gallucci M, Noce A, Bertucci P et al. Chronic treatment with statins increases the availability of selenium in the antioxidant defence systems of hemodialysis patients. J. Trace Elem. Med. Biol. 24(1), 27–30 (2010).
12.
van den Akker JM, Bredie SJ, Diepenveen SH, van Tits LJ, Stalenhoef AF, van Leusen R. Atorvastatin and simvastatin in patients on hemodialysis: effects on lipoproteins, C-reactive protein and in vivo oxidized LDL. J. Nephrol. 16(2), 238–244 (2003).
13.
Yigit F, Muderrisoglu H, Guz G et al. Comparison of intermittent with continuous simvastatin treatment in hypercholesterolemic patients with end stage renal failure. Jpn Heart J. 45(6), 959–968 (2004).
•• Compares the efficacy of intermittent versus continuous therapy of simvastatin in hemodialysis.
14.
Makowka A, Dryja P, Chwatko G, Bald E, Nowicki M. Treatment of chronic hemodialysis patients with low-dose fenofibrate effectively reduces plasma lipids and affects plasma redox status. Lipids Health Dis. 11, 47 (2012).
•• Studies the efficacy and safety of intermittent fenofibrate versus placebo in hemodialysis patients.
15.
Tkáč I, Molčányiová A, Javorský M, Kozárová M. Fenofibrate treatment reduces circulating conjugated diene level and increases glutathione peroxidase activity. Pharmacol. Res. 53(3), 261–264 (2006).
16.
Wu J, Song Y, Li H, Chen J. Rhabdomyolysis associated with fibrate therapy: review of 76 published cases and a new case report. Eur. J. Clin. Pharmacol. 65(12), 1169–1174 (2009).
17.
Ansquer J-C, Dalton RN, Caussé E, Crimet D, Le Malicot K, Foucher C. Effect of fenofibrate on kidney function: a 6-week randomized crossover trial in healthy people. Am. J. Kidney Dis. 51(6), 904–913 (2008).
18.
Ting R-D, Keech AC, Drury PL et al. Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment the FIELD study. Diabetes Care 35(2), 218–225 (2012).
19.
Clinical Trials Database: NCT02886299. https://clinicaltrials.gov/ct2/show/NCT02886299
20.
Hemodialysis Adequacy 2006 Work Group. Clinical practice guidelines for hemodyalisis adequacy – update 2006. Am. J. Kidney Dis. 48(1 Suppl. 1), S2–S90 (2006).
21.
Lopez-Gomez JM, Villaverde M, Jofre R, Rodriguez-Benitez P, Perez-Garcia R. Interdialytic weight gain as a marker of blood pressure, nutrition, and survival in hemodialysis patients. Kidney Int. Suppl. 67(Suppl. 93), S63–S68 (2005).
22.
Yang SC, Chiang CK, Hsu SP, Hung KY. Relationship between interdialytic weight gain and nutritional markers in younger and older hemodialysis patients. J. Ren. Nutr. 18(2), 210–222 (2008).
23.
Boudes P. Drug compliance in therapeutic trials: a review. Control. Clin. Trials 19(3), 257–268 (1998).
24.
Omran J, Al-Dadah A, Dellsperger KC. Dyslipidemia in patients with chronic and end-stage kidney disease. Cardiorenal Med. 3(3), 165–177 (2013).
25.
Ahmadpoor P, Eftekhar E, Nourooz-Zadeh J, Servat H, Makhdoomi K, Ghafari A. Glutathione, glutathione-related enzymes, and total antioxidant capacity in patients on maintenance dialysis. Iran J. Kidney Dis. 3(1), 22–27 (2009).
26.
Dummer CD, Thome’ FS, Zingano B, Lindoso A, Veronese FV. Acute effect of simvastatin on inflammation and oxidative stress in chronic kidney disease. J. Nephrol. 21(6), 900–908 (2008).
27.
Dogra G, Irish A, Chan D, Watts G. A randomized trial of the effect of statin and fibrate therapy on arterial function in CKD. Am. J. Kidney Dis. 49(6), 776–785 (2007).
28.
Chang JW, Yang WS, Min WK, Lee SK, Park JS, Kim SB. Effects of simvastatin on high-sensitivity C-reactive protein and serum albumin in hemodialysis patients. Am. J. Kidney Dis. 39(6), 1213–1217 (2002).
29.
Vernaglione L, Cristofano C, Muscogiuri P, Chimienti S. Does atorvastatin influence serum C-reactive protein levels in patients on long-term hemodialysis? Am. J. Kidney Dis. 43(3), 471–478 (2004).
30.
Harper CR, Jacobson TA. Managing dyslipidemia in chronic kidney disease. J. Am. Coll. Cardiol. 51(25), 2375–2384 (2008).
Information & Authors
Information
Published In
Copyright
© Future Medicine Ltd.
History
Published online: 19 June 2017
Keywords:
Topics
Authors
Metrics & Citations
Metrics
Article Usage
Article usage data only available from February 2023. Historical article usage data, showing the number of article downloads, is available upon request.
Citations
How to Cite
Randomized comparative efficacy and safety study of intermittent simvastatin versus fenofibrate in hemodialysis. (2017) Journal of Comparative Effectiveness Research. DOI: 10.2217/cer-2016-0076
Export citation
Select the citation format you wish to export for this article or chapter.